Clinical trials: GIST
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Gastrointestinal Stromal Tumors
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
- Trial name
- NCT00441155
- Testing
- Nilotinib, Imatinib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
Evaluate the reliability of morphology standards for GIST pathologic type, staging and grading by retrospective analyzing clinical data; on this basis, establish a GIST standardized and individualized treatment mode to maximum…
- Trial name
- NCT03381053
- Testing
- Imatinib 400mg
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Gastric GIST
Prognostic Factors Affecting Survival of Gastric GIST
Gastrointestinal stromal tumor (GIST) is the most common non-epithelial mesenchymal tumor of the gastrointestinal tract. Surgical treatment is the only curative therapy for primary localized GIST.
- Trial name
- NCT04269941
- Testing
- total or subtotal gastrectomy
- Volunteers
- 34 people
- Sponsor
- Université de Sousse
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Gastrointestinal Tract, Gastrointestinal Stromal Tumor
Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors
The exact incidence of subepithelial tumors (SETs) in the gastrointestinal (GI) tract is unknown, but the prevalence of gastric SETs detected during routine esophagogastroduodenoscopy is 0.36%.
- Trial name
- NCT02884154
- Testing
- Echotip ProCoreⓇ HD Ultrasound Biopsy Needle
- Volunteers
- 39 people
- Sponsor
- Pusan National University Hospital
Gastrointestinal Stromal Tumors
Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
This is a retrospective analysis and description of the preferred diagnostic and treatment methods employed on GIST on the Region of Coquimbo from 2003 to 2008.
- Trial name
- NCT00564265
- Testing
- Observation
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- Cirujanos la Serena
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
- Trial name
- NCT00069940
- Testing
- sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach, Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Mutations of tumor-related genes are dynamic. Gastrointestinal stromal tumor cells often are obviously more invasive in case of recurrence.
- Trial name
- NCT01505205
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumors (GIST) Registry
The goal of this observational research study is to establish a registry of information regarding how different physicians treat and manage patients with gastrointestinal stromal tumors (GISTs). Objectives: 1.
- Trial name
- NCT00507273
- Testing
- GIST Registry
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
- Trial name
- NCT03594422
- Testing
- HQP1351
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- Ascentage Pharma Group Inc.
GIST
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
- Trial name
- NCT03862885
- Testing
- Avapritinib
- Sponsor
- Blueprint Medicines Corporation
Somatostatin Receptor Positive, NETs
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following…
- Conditions
- Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor
- Trial name
- KinLET (NCT06441331)
- Testing
- Lutetium Lu 177-Edotreotide, Amino Acid Solution
- Where
- 9 sites in United States, France and 1 more
- Volunteers
- 20 people
- Sponsor
- ITM Solucin GmbH
Gastrointestinal Stromal Tumors
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore
- Trial name
- NCT00718211
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Gastric Cancers
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal…
- Trial name
- NCT01416714
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Chicago
Gastrointestinal Stromal Tumor
the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal Tumor
Gastric stromal tumor is a gastrointestinal mesenchymal tumor with malignant differentiation potential, the incidence increased year by year. The surgical resection is the primary treatment for it.
- Trial name
- NCT02763748
- Testing
- Laparoscopic endoscopy combined surgery, laparoscopic and endoscopic cooperative surgery, Single-arch laparoscopic and endoscopic cooperative surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Gastric Cancer, Leukemia
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
The drug that you are taking for your cancer, imatinib (GleevecTM), has recently been shown to have some new types of side effects. In some people, imatinib can affect how bones are made.
- Conditions
- Gastric Cancer, Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00580281
- Testing
- blood test, urine test, and bone density x-ray.
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center